Bacterial conjunctivitis
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Inflammation of the conjunctiva caused by a variety of bacterial agents.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Bacterial conjunctivitis
- Therapeutic area
- Infectious Disease
- bacterial conjunctivitis
- Bacteria caused conjunctival disease
- Bacteria conjunctival disease
- Severity
- Mild
- Acquired
- Inflammatory
Sources for recorded values
- Infectious Disease
- Ophthalmology
Sources for recorded values
- MONDO ID
- MONDO:0006668
- Parent condition
- MONDO:0003799
Related records
Broader conditions (16)
- Bacterial infectious disease
- Conjunctival disorder
- Conjunctivitis
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Disorder of orbital region
- Disorder of visual system
- Eye adnexa disorder
- Eye disorder
- Eye infectious disorder
- Human disease
- Infectious disease
- Inflammatory disease
Narrower conditions (5)
- Gonococcal conjunctivitis
- Inclusion conjunctivitis
- Ophthalmia neonatorum
- Pseudomembranous conjunctivitis
- Pseudomembranous diphtheritic conjunctivitis
Trials (35)
- A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
- A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
- A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
- AL-15469A for the Treatment of Bacterial Conjunctivitis
- AL-15469A for the Treatment of Bacterial Conjunctivitis
- An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
- Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
- Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults
- Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
- Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
- Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
- Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
- Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis
- Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis
- Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
- Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.
- Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
- Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
- Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers
Approved drugs (6)
- Azithromycin
- Azithromycin monohydrate
- Besifloxacin hydrochloride
- Gatifloxacin
- Levofloxacin
- Moxifloxacin hydrochloride
Drugs in development (14)
- Auriclosene Phase 2
- Besifloxacin Phase 3
- Dexamethasone Phase 3
- Fusidic acid Phase 3
- Moxifloxacin Phase 3
- Neomycin sulfate Phase 3
- Nepafenac Phase 2
- Ofloxacin Phase 3
- Pazufloxacin Phase 3
- Polymyxin B sulfate Phase 3
- Povidone-iodine Phase 3
- Tobramycin Phase 3
- Vancomycin Phase 3
- Vancomycin hydrochloride Phase 3